Edward Tenthoff
Stock Analyst at Piper Sandler
(2.98)
# 1,505
Out of 4,711 analysts
191
Total ratings
38.98%
Success rate
0.59%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MESO Mesoblast | Maintains: Overweight | $11 → $15 | $14.63 | +2.53% | 4 | Dec 19, 2024 | |
| XNCR Xencor | Upgrades: Overweight | $20 → $30 | $24.13 | +24.33% | 4 | Dec 2, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Overweight | $62 → $45 | $19.45 | +131.36% | 11 | Nov 27, 2024 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Overweight | $296 | $245.44 | +20.60% | 13 | Nov 18, 2024 | |
| MRNA Moderna | Reiterates: Overweight | $115 → $69 | $39.39 | +75.17% | 12 | Nov 18, 2024 | |
| OMGA Omega Therapeutics | Maintains: Overweight | $9 → $4 | $0.84 | +377.95% | 5 | Nov 15, 2024 | |
| KRON Kronos Bio | Downgrades: Neutral | $6 → $1 | $0.96 | +4.40% | 7 | Nov 14, 2024 | |
| TPST Tempest Therapeutics | Maintains: Overweight | $8 → $5 | $0.71 | +602.64% | 4 | Nov 13, 2024 | |
| CAMP Camp4 Therapeutics | Initiates: Overweight | $18 | $5.20 | +246.15% | 1 | Nov 5, 2024 | |
| CAPR Capricor Therapeutics | Initiates: Overweight | $35 | $13.07 | +167.79% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $1.88 | +485.11% | 6 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $53 | $23.99 | +120.93% | 5 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $2.70 | +640.74% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.54 | +94.81% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 → $5 | $0.20 | +2,400.00% | 6 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $1.01 | +197.03% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $6.93 | +130.88% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $40.72 | +157.86% | 6 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $34.08 | +164.08% | 3 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $12 | $1.10 | +990.91% | 6 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.68 | +257.14% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 | $0.28 | +1,692.11% | 4 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.80 | +177.78% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $15 | $4.35 | +244.83% | 3 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $56 | $40.66 | +37.73% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $10 | $9.45 | +5.82% | 3 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $55 | $18.48 | +197.62% | 6 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $31 | $0.83 | +3,655.75% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3 | $0.61 | +390.76% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $6 | $0.97 | +518.56% | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $9 | $0.92 | +883.07% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $20.29 | +116.91% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $14.68 | +152.04% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112,332 → $32,560 | $4.41 | +738,222.00% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $623.82 | -43.25% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $135 | $1.42 | +9,407.04% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $397.27 | -18.70% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $33.29 | +8.14% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $3.80 | +557.89% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.55 | +27,422.93% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $53 | $6.90 | +668.12% | 2 | Jan 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,380 | $1.03 | +133,880.58% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $701.85 | - | 11 | Feb 13, 2017 |
Mesoblast
Dec 19, 2024
Maintains: Overweight
Price Target: $11 → $15
Current: $14.63
Upside: +2.53%
Xencor
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $24.13
Upside: +24.33%
Arrowhead Pharmaceuticals
Nov 27, 2024
Maintains: Overweight
Price Target: $62 → $45
Current: $19.45
Upside: +131.36%
Alnylam Pharmaceuticals
Nov 18, 2024
Reiterates: Overweight
Price Target: $296
Current: $245.44
Upside: +20.60%
Moderna
Nov 18, 2024
Reiterates: Overweight
Price Target: $115 → $69
Current: $39.39
Upside: +75.17%
Omega Therapeutics
Nov 15, 2024
Maintains: Overweight
Price Target: $9 → $4
Current: $0.84
Upside: +377.95%
Kronos Bio
Nov 14, 2024
Downgrades: Neutral
Price Target: $6 → $1
Current: $0.96
Upside: +4.40%
Tempest Therapeutics
Nov 13, 2024
Maintains: Overweight
Price Target: $8 → $5
Current: $0.71
Upside: +602.64%
Camp4 Therapeutics
Nov 5, 2024
Initiates: Overweight
Price Target: $18
Current: $5.20
Upside: +246.15%
Capricor Therapeutics
Oct 21, 2024
Initiates: Overweight
Price Target: $35
Current: $13.07
Upside: +167.79%
Oct 11, 2024
Reiterates: Overweight
Price Target: $11
Current: $1.88
Upside: +485.11%
Sep 23, 2024
Reiterates: Overweight
Price Target: $53
Current: $23.99
Upside: +120.93%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $2.70
Upside: +640.74%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.54
Upside: +94.81%
Aug 13, 2024
Reiterates: Overweight
Price Target: $13 → $5
Current: $0.20
Upside: +2,400.00%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $1.01
Upside: +197.03%
Jun 28, 2024
Reiterates: Overweight
Price Target: $16
Current: $6.93
Upside: +130.88%
Jun 17, 2024
Reiterates: Overweight
Price Target: $105
Current: $40.72
Upside: +157.86%
Jun 17, 2024
Reiterates: Overweight
Price Target: $90
Current: $34.08
Upside: +164.08%
Jun 17, 2024
Maintains: Overweight
Price Target: $9 → $12
Current: $1.10
Upside: +990.91%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.68
Upside: +257.14%
Apr 3, 2024
Maintains: Overweight
Price Target: $5
Current: $0.28
Upside: +1,692.11%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $1.80
Upside: +177.78%
Feb 28, 2024
Maintains: Overweight
Price Target: $13 → $15
Current: $4.35
Upside: +244.83%
Feb 27, 2024
Maintains: Overweight
Price Target: $39 → $56
Current: $40.66
Upside: +37.73%
Dec 11, 2023
Maintains: Overweight
Price Target: $8 → $10
Current: $9.45
Upside: +5.82%
Oct 23, 2023
Maintains: Overweight
Price Target: $70 → $55
Current: $18.48
Upside: +197.62%
Aug 14, 2023
Maintains: Overweight
Price Target: $28 → $31
Current: $0.83
Upside: +3,655.75%
Dec 12, 2022
Initiates: Overweight
Price Target: $3
Current: $0.61
Upside: +390.76%
Nov 4, 2022
Maintains: Overweight
Price Target: $13 → $6
Current: $0.97
Upside: +518.56%
Sep 7, 2022
Maintains: Overweight
Price Target: $7 → $9
Current: $0.92
Upside: +883.07%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $20.29
Upside: +116.91%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $14.68
Upside: +152.04%
May 13, 2022
Maintains: Overweight
Price Target: $112,332 → $32,560
Current: $4.41
Upside: +738,222.00%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $623.82
Upside: -43.25%
Sep 20, 2021
Maintains: Overweight
Price Target: $105 → $135
Current: $1.42
Upside: +9,407.04%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $397.27
Upside: -18.70%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $33.29
Upside: +8.14%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $3.80
Upside: +557.89%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $0.55
Upside: +27,422.93%
Jan 6, 2020
Maintains: Overweight
Price Target: $26 → $53
Current: $6.90
Upside: +668.12%
Dec 11, 2017
Initiates: Overweight
Price Target: $1,380
Current: $1.03
Upside: +133,880.58%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $701.85
Upside: -